Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R-TM123 functions as a bridging module between Allo-RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.”In the company’s words, NCT05949125 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia, in Relapse
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up1
- May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | May 2027 | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026